What is the main purpose of this new credit agreement?

The primary purpose of the amended and restated revolving credit agreement is to provide Amgen with a $2.5 billion credit facility for general corporate purposes, including serving as a crucial liquidity backstop for its commercial paper program. This ensures financial flexibility and operational stability.

How does this new agreement compare to the previous one?

This new agreement amends and restates Amgen's existing revolving credit agreement from December 2, 2011. It establishes a $2.5 billion facility, with potential for expansion, and provides a defined term with extension options, indicating an updated and potentially more robust financial arrangement.

Are there any conditions or limitations associated with this credit facility?

Yes, the agreement includes customary affirmative and negative covenants, which typically cover areas such as limitations on mergers, asset sales, liens, and affiliate transactions. It also contains a covenant related to the maximum ratio of total debt to the sum of net worth and total debt.

Can Amgen increase the amount available under this credit line?

Yes, Amgen can request to increase the total commitment by up to an additional $500 million. However, any such increase is at the discretion of the participating banks and subject to certain customary requirements.

AMGN 8-K: Material Agreements

Summary

Amgen Inc. (AMGN) filed an 8-K on July 30, 2014, to report the entry into an amended and restated revolving credit agreement. This new agreement establishes a $2.5 billion credit facility, significantly enhancing the company's financial flexibility. The facility is intended for general corporate purposes and importantly serves as a liquidity backstop for Amgen's commercial paper program, ensuring operational continuity and financial stability. The agreement offers potential for an additional $500 million increase at Amgen's request, subject to bank discretion, and has an initial five-year term with options for two one-year extensions. This updated credit line replaces the previous agreement from December 2011 and reflects Amgen's proactive approach to managing its financial resources and capital structure.

Key Highlights

1Amgen entered into an amended and restated revolving credit agreement on July 30, 2014.
2The new credit facility has a total commitment of $2.5 billion.
3The facility is available for general corporate purposes and acts as a liquidity backstop for the commercial paper program.
4The company has the option to increase the commitments by up to $500 million.
5The initial term of the credit agreement is five years, with potential for two one-year extensions.
6The agreement replaces Amgen's prior revolving credit facility dated December 2, 2011.
7The credit agreement includes customary covenants and a maximum debt-to-equity ratio covenant.

AMGEN INC 8-K Report, Material Agreement (Jul 30, 2014)

Summary

Key Highlights

Frequently Asked Questions